Avirmax Biopharma, Inc., a leader in developing the next generation of AAV gene therapies, today announced the commencement of Investigational New Drug (IND)-enabling studies of ABI-201, a potential ...

Presented positive interim data through 52 weeks and beyond for 4D-150 in wet AMD from PRISM Phase 1/2 clinical trial highlighting robust and durable clinical activity across diverse patient populatio ...